Is your clinic ready for polynucleotides?
Look at your existing patient base and you will see there is a good chance you are already treating patients who could benefit from polynucleotides – even if they have never asked for them.
Patients concerned about declining skin quality may already be coming to you for other injectable or device-based treatments. Adding polynucleotides gives you another way to address these concerns, while expanding the regenerative options available within your clinic.
Successful integration starts with understanding where polynucleotides fit within your existing portfolio, which patients are most likely to benefit, and how to build them into a clear treatment pathway.
For practitioners considering introducing them, Plinest® is a product worth considering, thanks to its patented technology and a growing body of published research supporting its use.
Expand your treatment possibilities
One of the key advantages of polynucleotides is the breadth of concerns they can address within a clinic.
Plinest® is based on PN-HPT® (Polynucleotides Highly Purified Technology) and can support patients experiencing changes in hydration, elasticity, texture and fine lines, without adding volume or altering facial contours. Treatment can also extend beyond the face to areas such as the neck and décolleté.
The wider Plinest® range allows practitioners to tailor treatment further. Plinest® Eye is specifically designed for the delicate periocular area, addressing concerns such as fine lines, crepiness and declining skin quality. Newest® combines PN-HPT® with hyaluronic acid, making it particularly suited to patients where dehydration is a prominent concern alongside other signs of skin ageing.
The range also extends to hair restoration. Plinest® Hair is intended for use on the scalp and can be incorporated into treatment plans for patients experiencing hair thinning and reduced hair quality, alongside other established approaches to hair loss.
Having these different formulations within the same PN-HPT® range gives practitioners flexibility to address multiple patient concerns and build more individualised regenerative treatment plans.
This breadth of application is supported by a growing body of clinical research investigating Plinest® and PN-HPT® across different indications and patient populations.
Explore the evidence
With a growing number of polynucleotide products now available, looking at the evidence behind the specific product you are bringing into your clinic is important. Plinest® and its PN-HPT® technology have been investigated across a number of clinical studies, covering different patient populations, treatment areas and indications.
One of the most recent is a 2026 real-world observational study evaluating Plinest® in 66 adults receiving treatment to the face, neck and/or décolleté. Patients underwent three intradermal treatment sessions, with assessment three months after the final treatment. Visible improvements were reported across the treated areas using clinician and patient assessments, alongside high levels of patient satisfaction and a favourable safety profile.
Research has also looked specifically at Plinest® in Asian skin. A prospective study involving 30 patients assessed treatment for concerns including ageing and dry skin, enlarged pores, laxity and acne scarring. Participants received three treatments at four-week intervals and were followed for six months. Using 3D skin analysis alongside investigator and patient assessments, researchers reported significant improvements in skin surface, firmness, pigmentation and radiance, with benefits persisting at the six-month follow-up.
There is also evidence exploring how PN-HPT® can be incorporated alongside other aesthetic treatments. A randomised split-face study involving 20 women with moderate-to-severe nasolabial folds investigated PN-HPT® as a priming treatment before cross-linked hyaluronic acid. The PN-HPT®-treated side showed improvements in wrinkles and skin texture, while the authors also reported prolonged clinical benefits following subsequent HA treatment. This suggests an interesting potential role for polynucleotides within sequential treatment planning rather than solely as a standalone procedure.
Alongside these clinical studies, a consensus report developed by eight experienced aesthetic practitioners provides practical guidance on the use of PN-HPT® across different treatment areas. Recommendations were reached for the face, periocular area, neck and décolleté, hands, scalp and stretch marks, covering areas such as injection technique, dosage, treatment volumes, number of sessions and treatment intervals. For practitioners introducing Plinest® into clinic, this provides useful guidance on how the technology can be incorporated into day-to-day treatment protocols.
Prepare your practice
Once you have decided to introduce polynucleotides, start by considering where they fit within your existing treatment portfolio and patient journey.
Identify the right patients: Look beyond patients actively asking for polynucleotides. Those already attending for toxin, filler, skincare or device treatments may have concerns around texture, hydration, elasticity or fine lines that are not being fully addressed by their current plan. Incorporating skin-quality assessment into routine consultations can help identify suitable candidates.
Invest in product-specific training: Practitioners should understand the science behind PN-HPT®, appropriate patient selection, injection techniques, treatment areas and how the different products within the Plinest® range can be used. This is particularly important when choosing between Plinest®, Plinest® Eye and Newest® according to the patient’s presentation.
Create a clear treatment pathway: Decide how you will take patients from consultation through to treatment and review. Plinest® protocols typically involve a course of treatment rather than a single appointment, so explain the recommended number and frequency of sessions from the outset and schedule a review to assess progress. Standardised photography can be particularly useful for documenting gradual changes in skin quality.
Educate your wider team: Receptionists and patient coordinators are likely to receive questions about polynucleotides, so make sure they understand how the treatment differs from fillers and other injectables, why you choose Plinest®, the concerns it can address and the importance of consultation before treatment.
Develop a marketing plan. Give the launch of Plinest® the same consideration you would any new treatment. Update your website and treatment menu, introduce the treatment across email and social media, and create educational content explaining what polynucleotides are, how they work and the concerns they can address. Before-and-after imagery, practitioner-led videos and patient testimonials can help demonstrate results, while consistent education can build awareness among patients who may have heard of polynucleotides but do not yet understand where they could fit into their treatment plan.
DermaFocus, the UK distributor of Plinest®, provides practitioners with a wide range of resources to support each of these areas, from clinical training and treatment protocols to patient education and marketing materials, helping clinics integrate Plinest® effectively from launch onwards.
A valuable addition to your clinic
Polynucleotides have established an important place within medical aesthetics, giving practitioners another way to address skin quality across a broad range of patient concerns.
For clinics considering introducing them, Plinest® combines patented PN-HPT® technology with a growing body of clinical evidence, a range of formulations for different treatment needs and comprehensive training and support through DermaFocus.
With the right training, protocols and understanding of where polynucleotides fit within your existing offering, Plinest® can become a valuable and versatile addition to your clinic.